Initial Therapeutics
Initial Therapeutics: An ATP company developing small-molecule medicines to prevent pathogenic protein synthesis.
Founded
2020Initial Therapeutics: An ATP company developing small-molecule medicines to prevent pathogenic protein synthesis.
Initial Therapeutics, founded in South San Francisco, CA, is dedicated to developing small-molecule medicines aimed at preventing pathogenic protein synthesis. The company differentiates itself by focusing on interventions that inhibit the formation of harmful proteins rather than addressing them post-formation. This innovative approach positions Initial Therapeutics at the forefront of therapeutic development, targeting diseases at their molecular inception.
Notable figures associated with Initial Therapeutics include leading scientists and industry experts in the field of molecular medicine. The company has garnered attention from prominent investors in the biotech sector, reflecting confidence in its groundbreaking methodology. Initial Therapeutics' achievements include significant advancements in small-molecule therapeutics, contributing to the broader landscape of disease prevention and treatment. Their impact is evident in the potential for more effective and early-stage interventions in various pathogenic conditions.
Companies similar to Initial Therapeutics include Santi Therapeutics, Deep Apple Therapeutics, CoviCept Therapeutics and ProFound Therapeutics.
Initial Therapeutics was founded in 2020.
Initial Therapeutics' headquarters is located in New York City, NY, US.
Initial Therapeutics' most recent funding round was for $75M (USD) in May 2023.
As of May 1, 2023, Initial Therapeutics has disclosed funding of $78.8M (USD). Undisclosed round amounts are excluded.
Initial Therapeutics has 11 employees as of Feb 5, 2024.
ProFound Therapeutics
profoundtx.com
